Dear Ocumetics Team, Partners and Stakeholders,
I am thrilled to share an exciting update in our journey to revolutionize vision correction technology. Last week, we proudly announced, in a separate press release, the commencement of manufacturing for the Ocumetics accommodating intraocular lens (IOL). This is not just a milestone for our corporation, but a significant leap forward in eye care.
Our collaboration with Bioana, a leader in medical device design and manufacturing, marks a pivotal moment in our mission. Bioana’s state-of-the-art facilities and unmatched expertise make them the ideal partner for bringing our innovative lenses to life. Their commitment to excellence mirrors our own, and together, we are poised to set new standards in vision enhancement.
The Ocumetics accommodating IOL is designed to provide excellent visual acuity across all distances, addressing both near and far vision with great clarity. Our journey towards this groundbreaking development has been driven by a clear company vision: to create a lens that not only meets but exceeds the expectations of patients and eye care professionals alike. The initial production run of these lenses is a crucial step as we prepare for the upcoming first-in-human clinical study in the Dominican Republic. This study will provide us with essential data on the safety and efficacy of our lenses, guiding us as we navigate the regulatory landscape to bring this product to market.
I want to extend my deepest appreciation to Adriana Torres, COO and Chief Engineer at Bioana, and her exceptional team. Their enthusiasm and dedication to this project have been instrumental in reaching this milestone. We are honored to have Bioana as our manufacturing partner, and I am confident that their expertise will ensure the highest standards of quality and precision in producing our lenses.
In closing, let us celebrate this remarkable achievement and look forward to the exciting opportunities that lie ahead. Together, we are redefining the future of eye care, and I am honored to be on this journey with all of you.
Thank you for your dedication and support.
Warm regards,
Dean Burns
President & CEO,
Ocumetics Technology Corp.
Ocumetics Announces Completion of First Tranche of Debenture Private Placement for Net Proceeds of CA$2.82 Million Dear Ocumetics Investors, I am thrilled to share some exciting news that marks a significant milestone for our company and our mission to revolutionize eye care technology. I am pleased to announce that Ocumetics has successfully closed the first
Understanding the significance of the biocompatibility journey and why it’s essential for US FDA Approval Earlier this week, Ocumetics sent out a press release announcing that we completed our three-month biocompatibility study and received very favorable results. Receiving favorable results in this study is a critical aspect in the field of health care and medical
Tired of glasses? New lens technologies might offer a better way to see and experience the world. Anyone who relies on corrective eyewear has experienced its drawbacks. Maybe you are approaching your 50’s and need glasses to see up close. Maybe you left your reading glasses at home and find yourself asking for help deciphering
Ocumetics believes its accommodating lens technology could transform the eye care industry. Dr. Garth Webb, Ocumetics’ Founder and Chief Scientific Officer, thinks nothing is as beautiful as the lens in the human eye. “It’s this gorgeous, crystal-like orb that hides just behind the pupil,” he says. But it doesn’t stay that way forever. Inevitably, as
